Loading
A phase 1/2 trial of Fruquintinib in non-small-cell lung cancer and small-cell lung cancer, run by Immunitas Therapeutics, active and no longer recruiting.
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas is a phase 1/2 interventional study registered as NCT05565417 by Immunitas Therapeutics, with 67 participants enrolled, started 2022-11-28 and due to reach its primary completion in 2026-01. Interventions recorded: IMT-009, Fruquintinib. Conditions listed: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Colorectal cancer.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Colorectal cancer.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Cutaneous squamous cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.